Want to see SE:NANEXA full AI Analyst Report?
Top Page
Nanexa AB
(NANEXA)
Select Model
Select Model
Rating:50Neutral
Price Target:
kr6.50
▲(114.52% Upside)
Action:Reiterated
Date:08/28/26
The score is held back primarily by weak financial performance (ongoing losses, negative margins, and cash burn despite low leverage). Technical momentum is a clear positive, but valuation remains constrained by negative earnings and lack of dividend support.
Positive Factors
Very Low Leverage
Very low leverage gives Nanexa financial flexibility while it develops its pharmaceutical technology and partner programs. Limited debt exposure reduces interest and refinancing pressure, allowing more operating capacity to be directed toward research, development, and commercialization efforts.
Negative Factors
Persistent Unprofitability
Persistent operating and net losses show that Nanexa has not yet converted its technology and development activities into a consistently profitable business. Continued negative margins can constrain internal investment capacity and increase reliance on external financing or commercial milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Very Low Leverage
Very low leverage gives Nanexa financial flexibility while it develops its pharmaceutical technology and partner programs. Limited debt exposure reduces interest and refinancing pressure, allowing more operating capacity to be directed toward research, development, and commercialization efforts.
Read all positive factors
Nanexa AB (NANEXA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr1.04B
Dividend YieldN/A
Average Volume (3M)536.37K
Price to Earnings (P/E)―
Beta (1Y)-0.06
Revenue Growth104.76%
EPS Growth37.08%
CountrySE
Employees16
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.13
Shares Outstanding164,585,050
10 Day Avg. Volume919,048
30 Day Avg. Volume536,372
Financial Highlights & Ratios
PEG Ratio1.03
Price to Book (P/B)6.83
Price to Sales (P/S)19.19
P/FCF Ratio-26.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr112.20M
Nanexa AB Business Overview & Revenue Model
Company Description
Nanexa AB (publ) is a firm dedicated to developing advanced drug delivery solutions through nanotechnology. The company leverages its proprietary PharmaShell platform, a nanobased system that utilizes atomic layer deposition (ALD) technology for d...
How the Company Makes Money
Nanexa’s business model is centered on monetizing its drug delivery platform (PharmaShell) through partnering and related development activities. Revenue, when earned, would typically come from: (1) collaboration and licensing arrangements where p...
Nanexa AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.85M | 36.15M | 24.36M | 29.33M | 2.86M | 2.37M |
| Gross Profit | -5.57M | -8.85M | 46.69M | 59.16M | 3.40M | 4.31M |
| EBITDA | -9.07M | -2.92M | -18.99M | -70.79M | -53.86M | -32.92M |
| Net Income | -24.56M | -11.39M | -24.91M | -76.40M | -58.57M | -36.00M |
Balance Sheet | ||||||
| Total Assets | 154.68M | 138.14M | 91.82M | 132.26M | 170.19M | 165.00M |
| Cash, Cash Equivalents and Short-Term Investments | 52.56M | 44.57M | 10.29M | 65.17M | 81.18M | 105.66M |
| Total Debt | 795.00K | 2.20M | 3.71M | 4.03M | 6.27M | 3.83M |
| Total Liabilities | 21.81M | 36.61M | 20.90M | 36.43M | 61.10M | 13.70M |
| Stockholders Equity | 132.87M | 101.53M | 70.92M | 95.83M | 109.10M | 151.29M |
Cash Flow | ||||||
| Free Cash Flow | -27.96M | -26.21M | -54.55M | -76.91M | -43.29M | -50.92M |
| Operating Cash Flow | -6.44M | -1.46M | -26.43M | -42.66M | -7.87M | -25.13M |
| Investing Cash Flow | -27.33M | -24.75M | -28.12M | -34.25M | -35.42M | -25.79M |
| Financing Cash Flow | 46.06M | 60.49M | -327.00K | 60.89M | 18.81M | 143.89M |
Nanexa AB Technical Analysis
Positive
3.03
Price Trends
4.27
Positive
4.08
Positive
3.72
Positive
Market Momentum
0.47
Negative
79.45
Negative
86.35
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:NANEXA, the sentiment is Positive. The current price of 3.03 is below the 20-day moving average (MA) of 4.96, below the 50-day MA of 4.27, and below the 200-day MA of 3.72, indicating a bullish trend. The MACD of 0.47 indicates Negative momentum. The RSI at 79.45 is Negative, neither overbought nor oversold. The STOCH value of 86.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:NANEXA.
Nanexa AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | kr35.55B | 51.54 | 15.54% | ― | <0.01% | -6.75% | |
52 Neutral | kr121.64M | 1.07 | 23.67% | ― | 163.58% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr1.04B | -46.92 | -22.38% | ― | 104.76% | 37.08% | |
48 Neutral | kr91.02M | -2.42 | -106.23% | ― | -97.37% | 25.28% | |
46 Neutral | kr490.32M | -10.90 | ― | ― | 3.26% | 16.82% | |
41 Neutral | kr477.96M | -2.61 | -26.00% | ― | ― | 44.46% |
* Healthcare Sector Average
SE:NANEXA
Nanexa AB
6.33
4.05
177.02%
SE:CAMX
Camurus AB
587.00
-141.00
-19.37%
SE:NICA
Nanologica AB
0.37
-0.96
-72.24%
SE:XSPRAY
Xspray Pharma AB
10.08
-37.13
-78.65%
SE:SPAGO
Spago Nanomedical AB
0.11
-0.06
-34.86%
SE:ENZY
Enzymatica AB
2.02
-0.30
-12.93%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.